Dynamics of Anti-ABO(H) Antibody Expression in SARS-CoV-2-Infected Patients
ACS Chemical Biology · 2026
DOI: 10.1021/acschembio.6c00447 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, 2026. Verfasst von Tianwei Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, National Center for Functional Glycomics, CLS 11087-3 Blackfan C…. Hauptthemen laut MEDLINE: COVID-19, ABO Blood-Group System, Coronavirus Infections, Pneumonia, Viral. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, National Heart and Lung Institute.
Abstract (Originalsprache)
The association between ABO(H) blood groups and COVID-19 susceptibility and severity has been studied throughout the pandemic. However, the comprehensively tracked dynamic changes of antibodies to ABO(H) over the course of COVID-19 infection remain poorly characterized. Here, we present a longitudinal cohort study that tracked changes in anti-ABO(H) antibody levels and isotypes in serum of 65 COVID-19 patients. Sera were collected at (1) time of hospital admission, (2) 2–3 weeks after symptom onset, and (3) just before hospital discharge or death. Anti-ABO(H) glycan-specific IgG, IgM, and IgA isotypes were profiled using high-throughput Luminex assays, employing beads derivatized with glycans representing the major ABO(H) antigens. While each patient demonstrated unique repertoires of anti-ABO(H) antibodies, unexpected changes in isotypes were observed, indicating varied impact on naturally occurring antibody levels following SARS-CoV-2 infection. Interestingly, blood group O patients showed a higher likelihood of possessing anti-ABO(H) IgA than other blood types. Additionally, we identified autoantibodies against non-blood-group self-glycans in a small proportion of the cohort. Data suggest that exposure to virus represents an underappreciated factor influencing anti-ABO(H) antibody profiles. These results provide a deeper understanding of the potential interplay between anti-ABO(H) antibodies and progression of SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, National Center for Functional Glycomics, CLS 11087-3 Blackfan Circle, Boston, Massachusetts02115, United States.
- Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, 630E New Research Building, 77 Avenue Louis Pasteur, Boston, Massachusetts02115, United States.
- Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia30322, United States.
ORCID-Profile: Richard D Cummings
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- National Heart and Lung Institute
- National Institute of General Medical Sciences
Zitieren
APA
Jia, T., Mehta, A. Y., Patel, K. R., Charon, K. M., Heimburg-Molinaro, J., Roback, J. D., Stowell, S. R., & Cummings, R. D. (2026). Dynamics of Anti-ABO(H) Antibody Expression in SARS-CoV-2-Infected Patients. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00447
Vancouver
Jia T, Mehta AY, Patel KR, Charon KM, Heimburg-Molinaro J, Roback JD, et al. Dynamics of Anti-ABO(H) Antibody Expression in SARS-CoV-2-Infected Patients. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00447
BibTeX
@article{Jia2026,
author = {Jia, Tianwei and Mehta, Akul Y and Patel, Kashyap R and Charon, Kelsey M and Heimburg-Molinaro, Jamie and Roback, John D and Stowell, Sean R and Cummings, Richard D},
title = {Dynamics of Anti-ABO(H) Antibody Expression in SARS-CoV-2-Infected Patients},
journal = {ACS Chemical Biology},
year = {2026},
doi = {10.1021/acschembio.6c00447}
}
EUVIMED